965 related articles for article (PubMed ID: 30184160)
1. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
2. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
[TBL] [Abstract][Full Text] [Related]
4. Endocrine sequelae of immune checkpoint inhibitors.
Ntali G; Kassi E; Alevizaki M
Hormones (Athens); 2017 Oct; 16(4):341-350. PubMed ID: 29518754
[TBL] [Abstract][Full Text] [Related]
5. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
6. [Immune checkpoint inhibitors and endocrinological side effects].
Jørgensen LB; Bastholt L; Yderstræde K
Ugeskr Laeger; 2017 Dec; 179(49):. PubMed ID: 29212592
[TBL] [Abstract][Full Text] [Related]
7. A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
de Filette J; Andreescu CE; Cools F; Bravenboer B; Velkeniers B
Horm Metab Res; 2019 Mar; 51(3):145-156. PubMed ID: 30861560
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
9. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
10. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
11. French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Castinetti F; Albarel F; Archambeaud F; Bertherat J; Bouillet B; Buffier P; Briet C; Cariou B; Caron P; Chabre O; Chanson P; Cortet C; Do Cao C; Drui D; Haissaguerre M; Hescot S; Illouz F; Kuhn E; Lahlou N; Merlen E; Raverot V; Smati S; Verges B; Borson-Chazot F
Endocr Relat Cancer; 2019 Feb; 26(2):G1-G18. PubMed ID: 30400055
[TBL] [Abstract][Full Text] [Related]
12. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
[TBL] [Abstract][Full Text] [Related]
13. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
15. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
16. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
17. How we treat endocrine complications of immune checkpoint inhibitors.
Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
[TBL] [Abstract][Full Text] [Related]
18. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
19. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
20. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
